These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 17443397

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB, Shelton MJ, Studenberg S.
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [Abstract] [Full Text] [Related]

  • 4. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
    Brouwers J, Tack J, Augustijns P.
    Int J Pharm; 2007 May 24; 336(2):302-9. PubMed ID: 17207947
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
    Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT.
    J Clin Pharmacol; 2002 Aug 24; 42(8):887-98. PubMed ID: 12162471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA.
    Pharmacotherapy; 2008 Jan 24; 28(1):74-81. PubMed ID: 18154477
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M, Clay PG, Anderson PL, Glaros AG.
    Pharmacotherapy; 2009 Aug 24; 29(8):937-42. PubMed ID: 19637947
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.
    Pediatr Infect Dis J; 2014 Jan 24; 33(1):50-6. PubMed ID: 23811744
    [Abstract] [Full Text] [Related]

  • 13. Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base.
    Berlin M, Ruff A, Kesisoglou F, Xu W, Wang MH, Dressman JB.
    Eur J Pharm Biopharm; 2015 Jun 24; 93():267-80. PubMed ID: 25872159
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct 24; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
    Pérez-Elías MJ, Morellon ML, Ortega E, Hernández-Quero J, Rodríguez-Torres M, Clotet B, Felizarta F, Gutiérrez F, Pineda JA, Nichols G, Lou Y, Wire MB.
    Antimicrob Agents Chemother; 2009 Dec 24; 53(12):5185-96. PubMed ID: 19667283
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul 24; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 19. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects.
    Hens B, Masuy I, Deloose E, Mols R, Tack J, Augustijns P.
    Eur J Pharm Biopharm; 2020 May 24; 150():66-76. PubMed ID: 32113916
    [Abstract] [Full Text] [Related]

  • 20. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.
    Antimicrob Agents Chemother; 2007 Aug 24; 51(8):2982-4. PubMed ID: 17517848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.